Skip to content

Study · Systematic review · 2022

6 results

A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.

Lee K, Abraham S, Cleaver R

General hospital psychiatry14 Jul 2022Cited by 33 (Europe PMC)

PMID35863294 (opens in a new tab)DOI10.1016/j.genhosppsych.2022.07.006 (opens in a new tab)PepBankPUB-35863294
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in weight.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed lower weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in BMI.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed lower body mass index.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.
  3. 03HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in waist circumference.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed smaller waist size.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.
  4. 04HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in HbA1c.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed lower HbA1c.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.
  5. 05HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in cholesterol.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed lower cholesterol.

    Peptide
    Liraglutide
    Outcome
    DecreaseCholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.
  6. 06HumanSystematic reviewEfficacy outcome

    In people with antipsychotic-induced weight gain or obesity in schizophrenia and psychosis, a meta-analysis of liraglutide studies showed a significant improvement in LDL.

    In plain wordsIn people with schizophrenia or psychosis and weight gain, pooled liraglutide studies showed lower LDL cholesterol.

    Peptide
    Liraglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results for liraglutide showed statistically significant improvement in weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings on meta-analysis.
    1 context sentence
    Summary · context
    Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial (naltrexone-bupropion), and seven observational studies (five liraglutide, one semaglutide, one multiple WLMs) were identified.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.